Compare LSE & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | FLNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | China | United States |
| Employees | N/A | 20 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 61.8M |
| IPO Year | N/A | N/A |
| Metric | LSE | FLNA |
|---|---|---|
| Price | $4.11 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.2K | ★ 357.0K |
| Earning Date | 01-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $1.16 |
| 52 Week High | $7.40 | $2.03 |
| Indicator | LSE | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 40.38 |
| Support Level | N/A | $1.16 |
| Resistance Level | $5.35 | $1.80 |
| Average True Range (ATR) | 0.76 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 19.31 | 16.28 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.